Insulin costs as little as $2.28 to $3.37 per vial to manufacture, yet the list price of a single vial of popular analog insulin in the U.S. rose from $21 in 1999 to $322 by 2019, a 1,500% increase. The gap between production cost and pharmacy price isn’t explained by any single villain. It’s the result of a concentrated market, a tangled supply chain, aggressive patent strategies, and a rebate system that actually rewards higher sticker prices.
Three Companies Control the Market
Eli Lilly, Novo Nordisk, and Sanofi control over 90% of the global insulin market by value. That level of concentration means there’s virtually no price competition in the traditional sense. When one company raises its list price, the others tend to follow. This pattern played out clearly over two decades: the price of Eli Lilly’s Humalog climbed steadily, and competing products from Novo Nordisk and Sanofi “shadowed” those increases almost in lockstep.
With only three major players, there’s little incentive for any of them to undercut the others. Each company can raise prices knowing the other two will likely match, and patients who depend on insulin daily have no real option to stop buying.
The Rebate System That Rewards Higher Prices
Between the manufacturer and your pharmacy counter sits a layer of middlemen, most importantly pharmacy benefit managers (PBMs). These companies negotiate which drugs get covered by insurance plans. Their revenue comes largely from rebates and fees paid by manufacturers, and those rebates are calculated as a percentage of a drug’s list price. A higher list price means a bigger rebate check for the PBM.
This creates a perverse incentive. To get their insulin placed on an insurance plan’s preferred drug list, manufacturers raise list prices so they can offer PBMs fatter rebates. The Federal Trade Commission sued the three largest PBMs in 2024, alleging they artificially inflated insulin prices through exactly this mechanism. The FTC’s complaint described it as an “upside-down” market where manufacturers increased list prices specifically to feed PBMs’ appetite for larger rebates.
In theory, those rebates should flow back to patients. In practice, they often don’t reach you at the pharmacy. If you’re uninsured, in the deductible phase of your plan, or paying coinsurance based on the list price, you may end up paying more out of pocket for your insulin than the entire net cost of the drug to the insurance company. The people who can least afford it, those without robust coverage, absorb the most inflated prices.
How Many Hands Touch the Money
Every vial of insulin passes through a chain of intermediaries, each retaining a share of the total spending. The U.S. Department of Health and Human Services mapped this out: money enters the system from insurance reimbursements and patient copays, then flows through PBMs, pharmacies, wholesalers, and finally to the manufacturer. For brand-name drugs, manufacturers retained about 73.6% of total expenditures in 2022, while PBMs alone retained 18.3%, and wholesalers and pharmacies combined kept 8.1%.
That means roughly a quarter of what’s spent on brand insulin never reaches the company that made it. Each intermediary’s cut adds friction and cost to the system. The negotiations between these entities are private and contractual terms are confidential, making it nearly impossible for patients or even policymakers to see exactly where the money goes.
Patents That Never Seem to Expire
Insulin was discovered in 1921, so the original patents expired long ago. But manufacturers have found ways to extend their market exclusivity for decades through a strategy sometimes called “evergreening.” The key tactic: filing new patents after a product is already on the market, often not on the insulin itself but on the delivery device.
A study published in PLOS Medicine found that manufacturers of nine insulin products obtained patents filed after FDA approval, extending their protection by a median of six years. The most aggressive example involved Sanofi’s Lantus and Apidra pens, which each accumulated 18 post-approval patents, all on the delivery devices rather than the insulin inside. Across drug-device combinations, 67% had a device patent as their last to expire, stretching protection by a median of 5.2 additional years. In 17 cases, the final patent on a product didn’t even mention insulin in its claims. It covered something like the drive mechanism of the pen injector.
This matters because generic or biosimilar competitors can’t enter the market until these patents clear. Even when the insulin molecule itself is no longer protected, the surrounding web of device patents keeps competitors out.
Why Generics Have Been Slow to Arrive
Unlike a simple chemical pill, insulin is a biologic, a large, complex molecule produced by living cells. That means generic versions must go through the biosimilar approval pathway, which requires demonstrating that the product is highly similar to the original and produces no meaningful clinical differences. The FDA requires detailed studies on how the body’s immune system responds to a biosimilar insulin compared to the original, adding time and cost to the approval process.
Combine these regulatory hurdles with the patent thicket described above, and you get a market where biosimilar insulin has been painfully slow to reach pharmacy shelves. Even when biosimilars do get approved, they often launch at only modest discounts because the same PBM rebate dynamics still favor higher-priced products for formulary placement.
Analog Insulin Costs More Than It Needs To
Most people with diabetes today use analog insulins, which are engineered to act faster or last longer than older human insulin formulations. These analogs genuinely offer clinical advantages: more predictable absorption, fewer episodes of dangerously low blood sugar, and more flexible dosing. But the price premium is enormous. Long-acting analogs cost roughly four times more than the older intermediate-acting human insulin they replaced.
Research suggests that some of the higher acquisition cost is offset by lower overall medical spending, since analog users tend to need fewer blood sugar test strips, fewer treatments for low blood sugar episodes, and have lower rates of long-term complications. But those savings accrue to the health system over years, while the sticker shock hits your wallet every month. Meanwhile, older human insulin remains available at a fraction of the cost. Novo Nordisk’s human insulin can be purchased at Walmart for about $25 a vial, roughly $1 per day for an average user. For many patients, though, switching from an analog to older insulin isn’t medically straightforward and requires careful adjustment with a provider.
Recent Price Caps and What They Cover
Several forces have started pushing prices down. The Inflation Reduction Act capped out-of-pocket insulin costs at $35 per monthly prescription for Medicare Part D enrollees starting January 2023, with a similar cap for Medicare Part B taking effect in July 2023. In early 2023, Eli Lilly announced a 70% cut to its insulin list prices and a $35 monthly out-of-pocket cap, extending the cap to uninsured patients as well.
Before federal action, at least 12 states had already passed their own copay caps for commercially insured residents. These ranged from $25 per 30-day supply in New Mexico to $100 in states like Colorado, New York, Delaware, and Illinois. Washington, Maine, and West Virginia set caps at $35. Minnesota took a different approach, capping costs at $50 for a 90-day supply.
These caps make a real difference at the pharmacy counter, but they come with limitations. Most state laws apply only to people with commercial insurance, not to uninsured patients. Copay caps also don’t reduce the underlying list price. They shift costs within the insurance system rather than lowering them. The list price stays high, PBMs still collect their percentage-based rebates, and the fundamental pricing dynamics remain intact. For the millions of Americans who still fall through the gaps, whether because they’re underinsured, in a high-deductible plan, or living in a state without a cap, insulin remains one of the clearest examples of how the U.S. drug pricing system fails the people who depend on it most.